BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32164602)

  • 1. Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate.
    Wu D; Hu S; Hou Y; He Y; Liu S
    BMC Cancer; 2020 Mar; 20(1):199. PubMed ID: 32164602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
    Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
    J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
    Agretti P; Ferrarini E; Rago T; Candelieri A; De Marco G; Dimida A; Niccolai F; Molinaro A; Di Coscio G; Pinchera A; Vitti P; Tonacchera M
    Eur J Endocrinol; 2012 Sep; 167(3):393-400. PubMed ID: 22728346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
    Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
    Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
    Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
    Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of molecular biomarkers for enhancing the management of cytologically indeterminate thyroid nodules and thyroid cancer.
    Duick DS
    Endocr Pract; 2012; 18(4):611-5. PubMed ID: 22849877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic biomarkers of differentiated thyroid cancer.
    Kunavisarut T
    Endocrine; 2013 Dec; 44(3):616-22. PubMed ID: 23645523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-gene molecular diagnostic model for thyroid cancer.
    Prasad NB; Kowalski J; Tsai HL; Talbot K; Somervell H; Kouniavsky G; Wang Y; Dackiw AP; Westra WH; Clark DP; Libutti SK; Umbricht CB; Zeiger MA
    Thyroid; 2012 Mar; 22(3):275-84. PubMed ID: 22280184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Molecular Testing for the Indeterminate Thyroid FNA.
    Rossi ED; Pantanowitz L; Faquin WC
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31547603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The frequency of malignant disease in cytological group of suspected cancer (ultrasound-guided fine-needle aspiration biopsy of nonpalpable thyroid nodules)].
    Miseikyte-Kaubriene E; Ulys A; Trakymas M
    Medicina (Kaunas); 2008; 44(3):189-94. PubMed ID: 18413985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
    Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
    J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
    Pagan M; Kloos RT; Lin CF; Travers KJ; Matsuzaki H; Tom EY; Kim SY; Wong MG; Stewart AC; Huang J; Walsh PS; Monroe RJ; Kennedy GC
    BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):6. PubMed ID: 26818556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A panel of four genes accurately differentiates benign from malignant thyroid nodules.
    Wang QX; Chen ED; Cai YF; Li Q; Jin YX; Jin WX; Wang YH; Zheng ZC; Xue L; Wang OC; Zhang XH
    J Exp Clin Cancer Res; 2016 Oct; 35(1):169. PubMed ID: 27793213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing Identifies a Highly Accurate miRNA Panel That Distinguishes Well-Differentiated Thyroid Cancer from Benign Thyroid Nodules.
    Mazeh H; Deutch T; Karas A; Bogardus KA; Mizrahi I; Gur-Wahnon D; Ben-Dov IZ
    Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):858-863. PubMed ID: 30049841
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
    Freitas BC; Cerutti JM
    Mol Cell Endocrinol; 2010 May; 321(1):77-85. PubMed ID: 19932149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application.
    Ralhan R; Veyhl J; Chaker S; Assi J; Alyass A; Jeganathan A; Somasundaram RT; MacMillan C; Freeman J; Vescan AD; Witterick IJ; Walfish PG
    Thyroid; 2015 Nov; 25(11):1224-34. PubMed ID: 26131603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
    Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
    Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.